{
  "id": 14708353,
  "title": "Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study",
  "url": "https://urgent.news/2026/10/15/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T13:41:45.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "Enables expansion of ongoing vitiligo clinical study to U.S. investigational sites Topline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration (FDA) has cleared the…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}